These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36420193)

  • 1. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART).
    Bryant JM; Palm RF; Liveringhouse C; Boyer E; Hodul P; Malafa M; Denbo J; Kim D; Carballido E; Fleming JB; Hoffe S; Frakes J
    Adv Radiat Oncol; 2022; 7(6):101045. PubMed ID: 36420193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART).
    Bryant JM; Palm RF; Herrera R; Rubens M; Hoffe SE; Kim DW; Kaiser A; Ucar A; Fleming J; De Zarraga F; Hodul P; Aparo S; Asbun H; Malafa M; Jimenez R; Denbo J; Frakes JM; Chuong MD
    Cancer Control; 2023; 30():10732748221150228. PubMed ID: 36598464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer.
    Chuong MD; Herrera R; Kaiser A; Rubens M; Romaguera T; Alvarez D; Kotecha R; Hall MD; McCulloch J; Ucar A; DeZarraga F; Aparo S; Joseph S; Asbun H; Jimenez R; Narayanan G; Gutierrez AN; Mittauer KE
    Front Oncol; 2022; 12():888462. PubMed ID: 35814383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study.
    Chuong MD; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Raphael Pfeffer M; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Jitendra Parikh P
    Radiother Oncol; 2024 Feb; 191():110064. PubMed ID: 38135187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
    Parikh PJ; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Pfeffer MR; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Chuong MD
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):799-808. PubMed ID: 37210048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK.
    Nugent K; Mukherjee S; Teoh S; George B; Martin A; Gaya A; Aznar-Garcia L; Chu K; Robinson M; Maughan T; Good J
    Clin Oncol (R Coll Radiol); 2024 Sep; 36(9):576-584. PubMed ID: 38902119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.
    Michalet M; Bordeau K; Cantaloube M; Valdenaire S; Debuire P; Simeon S; Portales F; Draghici R; Ychou M; Assenat E; Dupuy M; Gourgou S; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
    Front Oncol; 2022; 12():842402. PubMed ID: 35356227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study.
    Bordeau K; Michalet M; Keskes A; Valdenaire S; Debuire P; Cantaloube M; Cabaillé M; Portales F; Draghici R; Ychou M; Assenat E; Mazard T; Samalin E; Gauthier L; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience.
    Lee HI; Kang HC; Chie EK
    Front Oncol; 2022; 12():974454. PubMed ID: 36505838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy
    Kutuk T; Herrera R; Mustafayev TZ; Gungor G; Ugurluer G; Atalar B; Kotecha R; Hall MD; Rubens M; Mittauer KE; Contreras JA; McCulloch J; Kalman NS; Alvarez D; Romaguera T; Gutierrez AN; Garcia J; Kaiser A; Mehta MP; Ozyar E; Chuong MD
    Adv Radiat Oncol; 2022; 7(6):100978. PubMed ID: 35647412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma.
    Webking S; Sandoval ML; Chuong MD; Ucar A; Aparo S; De Zarraga F; Sahin I; Biachi T; Kim DW; Hoffe SE; Frakes JM; Palm RF
    Cancer Control; 2023; 30():10732748231219069. PubMed ID: 38038261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer.
    Chuong MD; Bryant J; Mittauer KE; Hall M; Kotecha R; Alvarez D; Romaguera T; Rubens M; Adamson S; Godley A; Mishra V; Luciani G; Gutierrez AN
    Pract Radiat Oncol; 2021; 11(2):134-147. PubMed ID: 32947042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causes of Death Among Patients With Initially Inoperable Pancreas Cancer After Induction Chemotherapy and Ablative 5-fraction Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy.
    Chuong MD; Herrera R; Ucar A; Aparo S; De Zarraga F; Asbun H; Jimenez R; Asbun D; Narayanan G; Joseph S; Kotecha R; Hall MD; Mittauer KM; Alvarez D; McCulloch J; Romaguera T; Gutierrez A; Kaiser A
    Adv Radiat Oncol; 2023; 8(1):101084. PubMed ID: 36483070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer outcome-local treatment with radiation using MRI-LINAC.
    Almog G; Pfeffer RM; Zalmanov S; Grinberg V; Lipsky Y; Chernomordikov E; Levin D; Apter S; Arsenault O; Epstein D; Tamimi Q; Hod K; Limon D; Golan T; Ben-Aharon I; Lawrence YR; Ben-David MA
    Front Oncol; 2023; 13():1289919. PubMed ID: 38074644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation.
    Hassanzadeh C; Rudra S; Bommireddy A; Hawkins WG; Wang-Gillam A; Fields RC; Cai B; Park J; Green O; Roach M; Henke L; Kim H
    Adv Radiat Oncol; 2021; 6(1):100506. PubMed ID: 33665480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
    Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
    Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer.
    Henke LE; Stanley JA; Robinson C; Srivastava A; Contreras JA; Curcuru A; Green OL; Massad LS; Kuroki L; Fuh K; Hagemann A; Mutch D; McCourt C; Thaker P; Powell M; Markovina S; Grigsby PW; Schwarz JK; Chundury A
    Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):379-389. PubMed ID: 34474109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.
    Yoon SM; Luterstein E; Chu FI; Cao M; Lamb J; Agazaryan N; Low D; Raldow A; Steinberg ML; Lee P
    Cancer Med; 2021 Sep; 10(17):5897-5906. PubMed ID: 34288538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.
    Chuong MD; Frakes JM; Figura N; Hoffe SE; Shridhar R; Mellon EA; Hodul PJ; Malafa MP; Springett GM; Centeno BA
    J Gastrointest Oncol; 2016 Apr; 7(2):221-7. PubMed ID: 27034789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.